Table 1.
Clinical trials of TIGIT inhibitors.
| TIGIT Inhibitor | Sponsor | Isotype | Identifiers | Cancer Type | Combination | Phase | Recruitment Status | Start Date |
|---|---|---|---|---|---|---|---|---|
| ASP-8374 | Astellas Pharma Inc. | IgG4 | NCT03260322 | Advanced solid tumor | ASP-8374 alone; Pembrolizumab (anti-PD-1) |
Phase 1b | No longer recruiting | 8 September 2017 |
| NCT03945253 | Advanced solid tumor | ASP-8374 alone | Phase 1 | No longer recruiting | 5 August 2019 | |||
| BGB-A1217 | BeiGene Co Ltd. | IgG1 | NCT04047862 | Advanced solid tumor | Tislelizumab (anti-PD-1) | Phase 1 | Recruiting | 26 August 2019 |
| BMS-986207 | Bristol-Myers Squibb Co. | IgG1 (Fc receptor disabled) |
NCT02913313 | Advanced solid tumor | BMS-986207 alone; Nivolumab (anti-PD-1) |
Phase 1/2 | No longer recruiting | 29 November 2016 |
| NCT04150965 | Multiple myeloma | BMS-986207 alone; Dexamethasone+Pomalidomide |
Phase 1/2 | Recruiting | 16 April 2018 | |||
| NCT04570839 | Advanced solid tumor | COM-701 (PVRIG inhibitor) + Nivolumab (anti-PD-1) | Phase 1/2 | Recruiting | 31 August 2020 | |||
| NCT04065425 | Multiple myeloma | Dexamethasone + Pomalidomide | Phase 1/2 | Not yet recruiting | 1 October 2019 | |||
| COM-902 | Compugen Ltd. | IgG4 | NCT04354246 | Advanced solid tumor | COM-902 alone | Phase 1 | Recruiting | 31 March 2020 |
| AB154 (Domvanalimab) |
Arcus Biosciences Inc. | IgG1 (Fc receptor disabled) |
NCT03628677 | Advanced malignancy | AB154 alone; Zimberelimab (anti-PD-1) |
Phase 1 | Recruiting | 12 September 2018 |
| NCT04656535 | Recurrent Glioblastoma | Zimberelimab (anti-PD-1) | Phase 1 | Not yet recruiting | 31 January 2021 | |||
| NCT04262856 | PD-L1 positive lung cancer | Zimberelimab (anti-PD-1); Zimberelimab + etrumadenant (A2aR and A2bR antagonist) |
Phase 2 | Recruiting | 28 May 2020 | |||
| EOS-884448 | iTeos Therapeutics | IgG1 | NCT04335253 | Advanced tumor | EOS-884448 alone | Phase 1/2 | Recruiting | 18 February 2020 |
| Etigilimab (OMP-313M32) |
OncoMed | IgG1 | NCT03119428 | Advanced solid tumor | Etigilimab alone; Nivolumab (anti-PD-1) |
Phase 1 | Terminated | 2 May 2017 |
| IBI-939 | Innovent Biologics Inc. | Not disclosed | NCT04353830 | Advanced tumor | IBI-939 alone; Sintilimab (anti-PD-1) |
Phase 1a | Recruiting | 22 May 2020 |
| NCT04672356 | Advanced lung cancer | Sintilimab (anti-PD-1) | Phase 1a | Not yet recruiting | 28 January 2021 | |||
| NCT04672369 | Advanced NSCLC | Sintilimab (anti-PD-1) | Phase 1b | Not yet recruiting | 6 June 2021 | |||
| M-6223 | Serono Research Institute Inc, Merck KGaA | Not disclosed | NCT04457778 | Advanced solid tumor | M-6223 alone; Bintrafusp alfa (TGF beta ligand inhibitor) |
Phase 1 | Recruiting | 10 July 2020 |
| Vibostolimab (MK-7684) | Merck Sharp & Dohme Corp. | IgG1 | NCT02964013 | Advanced solid tumor | Vibostolimab alone; Pembrolizumab (anti-PD-1); Pembrolizumab + Pemetrexed + Carboplatin; Pembrolizumab + Carboplatin or Cisplatin + Etoposide |
Phase 1 | Recruiting | 13 December 2016 |
| NCT04305054 | Advanced melanoma | Pembrolizumab (anti-PD-1); | Phase 1/2 | Recruiting | 1 July 2020 | |||
| NCT04303169 | Melanoma | Pembrolizumab (anti-PD-1) | Phase 1/2 | Recruiting | 26 June 2020 | |||
| NCT04305041 | Refractory melanoma | Pembrolizumab + Quavonlimab (anti-CTLA4) | Phase 1/2 | Recruiting | 26 June 2020 | |||
| NCT04165070 | Advanced NSCLC | Pembrolizumab + Carboplatin + Paclitaxel; Pembrolizumab + Pemetrexed |
Phase 2 | Recruiting | 19 December 2019 | |||
| NCT02861573 | Prostate cancer | Pembrolizumab (anti-PD-1) | Phase 1/2 | Recruiting | 17 November 2016 | |||
| Tiragolumab (MTIG7192A) | Genentech Inc., Chugai Pharmaceutical Co. Ltd., Roche Holding AG | IgG1 | NCT04045028 | Relapse/Refractory Multiple myeloma and B-cell Non-Hodgkin lymphoma | Tiragolumab alone; Daratumumab (anti-CD38); Rituximab (anti-CD20) |
Phase 1 | Recruiting | 22 July 2019 |
| NCT02794571 | Metastatic solid tumor | Tiragolumab alone; Atezolizumab (anti-PD-L1); Chemotherapy (Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed) |
Phase 1 | Recruiting | 23 May 2016 | |||
| NCT03281369 | Metastatic esophageal cancer | Atezolizumab (anti-PD-L1); Atezolizumab + Cisplatin+5FU |
Phase 1/2 | Recruiting | 13 October 2017 | |||
| NCT04513925 | NSCLC | Atezolizumab (anti-PD-L1) | Phase 3 | Recruiting | 24 August 2020 | |||
| NCT04294810 | Metastatic NSCLC, PD-L1 selected | Atezolizumab (anti-PD-L1) | Phase 3 | Recruiting | 04 March 2020 | |||
| NCT04665843 | Metastatic head and neck cancer, PD-L1 positive | Atezolizumab (anti-PD-L1) | Phase 2 | Not yet recruiting | 21 January 2021 | |||
| NCT04543617 | Esophagus squamous cell carcinoma | Atezolizumab (anti-PD-L1) | Phase 3 | Recruiting | 28 September 2020 | |||
| NCT04300647 | Metastasis/Recurrent uterine cervix tumor, PD-L1 positive | Atezolizumab (anti-PD-L1) | Phase 2 | Recruiting | 30 June2020 | |||
| NCT03563716 | NSCLC, chemotherapy-naïve | Atezolizumab (anti-PD-L1) | Phase 2 | No longer recruiting | 10 August 2018 | |||
| NCT04665856 | Small-cell lung cancer | Atezolizumab + Carboplatin + Etoposide | Phase 3 | Recruiting | 4 January 2021 | |||
| NCT04619797 | Metastatic NSCLC | Atezolizumab + Pemetrexed + Carboplatin or Cisplatin | Phase 2 | Recruiting | 11 December 2020 | |||
| NCT04584112 | Triple-negative breast cancer | Atezolizumab + Nab-paclitaxel; Atezolizumab + Nab-pac-carbo-AC; Atezolizumab+Nab-pac-AC; |
Phase 1b | Recruiting | 28 September 2020 | |||
| NCT04256421 | Metastatic small-cell lung cancer | Atezolizumab + Carboplatin + Etoposide | Phase 3 | Recruiting | 4 February 2020 | |||
| NCT04540211 | Metastatic esophageal cancer | Atezolizumab + Paclitaxel + Cisplatin | Phase 3 | Recruiting | 4 November 2020 | |||
| NCT04524871 | Metastatic hepatocellular carcinoma | Atezolizumab + Bevacizumab (anti-VEGF) | Phase 1/2 | Recruiting | 2 November 2020 | |||
| NCT03869190 | Advanced urothelial carcinoma | Atezolizumab (anti-PD-L1) | Phase 1/2 | Recruiting | 1 June 2019 | |||
| NCT03193190 | Metastatic pancreatic ductal adenocarcinoma | Atezolizumab + Nab-Paclitaxe l+ Gemcitabine | Phase 1/2 | Recruiting | 5 July 2017 |
PD-L1: programmed death-ligand 1; NSCLC: non-small cell lung cancer; TGF: transforming growth factor; VEGF: vascular endothelial growth factor.